Repligen Corporation (RGEN) shares climbed 6.1% to $173.88 as of October 10, 2026, a significant gain from the prior close of $163.84. BestStocks flagged the session as a major change for RGEN. Below, we break down what changed for RGEN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
RGEN climbed 6.1% to $173.88
RGEN climbed 6.1% in its latest session, moving from $163.84 to $173.88.
ValuationMedium confidence
Rel. volume
1.2×
Normal
Vs peers
—
No comparable peers
Market cap
$9.8B
NASDAQ Global Select
Analyst target
$174
+0.0% vs price
Price chart
Sep 9 – Oct 9
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Repligen Corporation investors
For Repligen Corporation investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 6.1% price move. Weighing against that: Repligen completed its acquisition of BioLife Solutions, announced today via Globe Newswire and formalized in an SEC 8-K filing; Repligen Corporation (RGEN) moved -5.84% from $145.49 to $136.99 on 2026-07-21. Wall Street's consensus price target sits at $173.86, implying +0.0% upside from $173.88. BestStocks rates the overall signal quality medium (60/100). With earnings roughly 24 days out, the next report is the most likely near-term test of the move.
RGEN price reaction
RGEN last traded at $173.88, up $10.04 (+6.13%) from the previous close of $163.84. The session traded on 1.2× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $163.84 and $194.57, and it currently sits about 33% of the way up that band.
Bullish and bearish analyst opinions on Repligen Corporation (RGEN)
The consensus analyst price target on Repligen Corporation (RGEN) is $173.86, 0.0% above the recent $173.88. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RGEN line up.
▲ The bullish case
+Wall Street's consensus price target of $173.86 implies +0.0% upside from $173.88.
+The Street's most bullish target is $225.00 (+29.4%).
+Material positive event.
+Strong 6.1% price move.
+Positive price momentum.
▼ The bearish case
−The most bearish analyst target is $142.00 (-18.3%).
−Repligen completed its acquisition of BioLife Solutions, announced today via Globe Newswire and formalized in an SEC 8-K filing.
−Repligen Corporation (RGEN) moved -5.84% from $145.49 to $136.99 on 2026-07-21.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Repligen completed its acquisition of BioLife Solutions, announced today via Globe Newswire and formalized in an SEC 8-K filing. The stock fell 6.53% to $177.12 on volume 1.30x the 180-minute average, suggesting market skepticism about deal terms or integration prospects despite the milestone.
News2026-10-06-7.7%
Repligen completed its acquisition of BioLife Solutions, expanding its bioprocessing technology portfolio.
Filings2026-10-06-7.7%
Repligen Corporation (RGEN) filed a new 8-K on October 6, 2026. The filing details were not disclosed in available sources.
Material / Earnings2026-10-05+4.3%
Repligen Corporation (RGEN) moved +6.01% from $178.75 to $189.50 on 2026-10-05. We checked news, earnings announcements, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
News2026-10-05+4.3%
BioLife Solutions shareholders approve merger with Repligen, clearing final regulatory hurdle for transaction.
Repligen beat Q2 earnings estimates on October 1, 2026, yet the stock fell 7.10% to $178.57 from $192.23 intraday (per Yahoo Finance). Volume of 1.47x normal suggests active selling despite the positive earnings surprise, indicating a sell-the-news or guidance-driven reaction.
Repligen Corporation moved +2.15% intraday from $184.53 to $188.50. Repligen Corporation (RGEN) stock is up today because it is continuing a multi-week momentum surge that pushed the stock to a new 52-week high of $190.01.While there is no new company-specific catalyst filed today, the upward movement is driven by a broader wave of investor optimism, recent Wall Street price target upgrades (including Argus raising its target to $196.00), and continued positive sentiment from its raised 2026 financial guidance and pending BioLife Solutions acquisition. ## Repligen Corp (RGEN) $188.75 2.29% today As of Sep 24, 1:31 PM EDT • Disclaimer 10:00 AM 11:00 AM 12:00 PM 1:00 PM 186 188 Prev close $184.53 Sep 24, 2026 9:30 AM - 1:31 PM 1D 5D 1M 6M YTD 1Y 5Y Max| Open 184.10 | Mkt cap $10.65B USD | 52-wk high 190.01 | | High 190.01 | P/E ratio 257.28 | 52-wk low 100.99 | | Low 183.75 | Div yield- | ### Core Factors Driving the Recent Gains: - Analyst Upgrades: Research firms have continuously revised their outlooks upward, with recent reports boosting price targets up to $196.00 and UBS initiating coverage with a Buy rating and a $225 target earlier this month. - Sector Rotation & ETF Inflows: Life sciences tools and bioprocessing stocks are experiencing a str
Filings2026-09-15+4.0%
Repligen Corporation (RGEN) filed a new 8-K on September 15, 2026. The filing details were not disclosed in available sources.
In-depth RGEN event analyses
Permanent, dated analyses of RGEN's most significant sessions.
RGEN climbed 6.1% to $173.88. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did RGEN stock rise?
RGEN gained 6.13% ($10.04) versus the prior close of $163.84, last trading at $173.88 on 1.2× average volume.
When is Repligen Corporation's next earnings date?
RGEN's next earnings report is estimated for 2026-11-03 — about 24 days away.
What is the analyst price target for RGEN?
The consensus analyst price target for RGEN is $173.86, about 0.0% above the current $173.88. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks RGEN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared RGEN-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for RGEN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
